Millions of Americans have experimented with prescription weight-loss drugs like Zepbound and Wegovy, achieving significant weight loss and health improvements in many cases. However, a substantial number of users eventually stop taking these medications, often marketed as long-term treatments. New research confirms that the benefits are not sustained: individuals who discontinue these drugs rapidly regain lost weight and see their cardiovascular health metrics revert to pre-treatment levels within roughly two years.
The Speed of Reversal
A review study published in The BMJ found that weight regain occurs approximately four times faster after stopping weight-loss drugs compared to ceasing dieting or exercise regimens. On average, individuals regain about one pound (0.4 kilograms) per month after cessation. Crucially, cardiometabolic markers—including blood glucose, blood pressure, and cholesterol—also deteriorate, returning to baseline levels within 1.4 to 1.7 years.
The Metabolic Impact
The study encompassed various weight-loss medications, including older GLP-1 drugs (like semaglutide) as well as non-GLP-1 options such as orlistat and phentermine/topiramate combinations. Researchers contrasted these results with data from behavioral interventions (dieting and exercise). The key takeaway is that discontinuing medication triggers a faster weight rebound than stopping traditional lifestyle changes.
Why this matters: This highlights a critical issue in obesity treatment. While drugs offer rapid results, stopping them without a sustained behavioral plan leads to a quicker return to unhealthy metabolic states. The body doesn’t simply “pause” weight regain; it accelerates it.
The Role of Behavior and Physiology
Experts emphasize that weight loss from drugs involves losing fat, muscle, and bone mass. Without ongoing exercise, the regained weight tends to be primarily fat, meaning individuals may end up metabolically worse off even if they return to their initial weight.
“If you look at the study’s charts, you might regain more weight and end up worse off than you were before,” says Rozalina McCoy, an endocrinologist at the University of Maryland.
The study reinforces that obesity treatment is not merely about willpower. GLP-1 medications suppress appetite effectively, but when this effect vanishes, maintaining weight loss through behavior alone becomes exceedingly difficult.
Implications for Long-Term Care
Researchers suggest transitioning patients into behavioral programs (diet or exercise) immediately upon stopping medication, but more trials are needed to validate this approach. The findings also raise concerns about insurance coverage: abrupt changes or limitations on medication access may have long-term health consequences.
Ultimately, the study underscores the reality that weight-loss drugs are not a “cure.” Stopping them without ongoing lifestyle management leads to predictable and rapid deterioration of health benefits.
